Ergomed PLC (LON:ERGO)‘s stock had its “buy” rating restated by analysts at Stifel Nicolaus in a research note issued on Monday. They presently have a GBX 315 ($3.85) price objective on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 72.60% from the stock’s current price.

A number of other research analysts have also recently weighed in on ERGO. Numis Securities Ltd restated a “buy” rating and set a GBX 277 ($3.39) target price on shares of Ergomed PLC in a research note on Monday. N+1 Singer restated a “buy” rating and set a GBX 275 ($3.36) target price on shares of Ergomed PLC in a research note on Tuesday, November 29th.

Ergomed PLC (LON:ERGO) opened at 188.00 on Monday. The stock’s 50 day moving average price is GBX 208.03 and its 200-day moving average price is GBX 154.24. The company’s market capitalization is GBX 58.50 million. Ergomed PLC has a 52 week low of GBX 117.00 and a 52 week high of GBX 216.88.

Your IP Address:

Ergomed PLC Company Profile

Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services.

Receive News & Ratings for Ergomed PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ergomed PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.